These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 23151131)
1. Emerging role of the ubiquitin-proteasome system as drug targets. Kar G; Keskin O; Fraternali F; Gursoy A Curr Pharm Des; 2013; 19(18):3175-89. PubMed ID: 23151131 [TBL] [Abstract][Full Text] [Related]
2. The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases. Ying Z; Wang H; Wang G Curr Pharm Des; 2013; 19(18):3305-14. PubMed ID: 23151138 [TBL] [Abstract][Full Text] [Related]
3. Drug discovery in the ubiquitin-proteasome system. Nalepa G; Rolfe M; Harper JW Nat Rev Drug Discov; 2006 Jul; 5(7):596-613. PubMed ID: 16816840 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Edelmann MJ; Nicholson B; Kessler BM Expert Rev Mol Med; 2011 Nov; 13():e35. PubMed ID: 22088887 [TBL] [Abstract][Full Text] [Related]
5. The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim? Dennissen FJ; Kholod N; van Leeuwen FW Prog Neurobiol; 2012 Feb; 96(2):190-207. PubMed ID: 22270043 [TBL] [Abstract][Full Text] [Related]
6. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. Motegi A; Murakawa Y; Takeda S Cancer Lett; 2009 Sep; 283(1):1-9. PubMed ID: 19201084 [TBL] [Abstract][Full Text] [Related]
7. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Tundo GR; Sbardella D; Santoro AM; Coletta A; Oddone F; Grasso G; Milardi D; Lacal PM; Marini S; Purrello R; Graziani G; Coletta M Pharmacol Ther; 2020 Sep; 213():107579. PubMed ID: 32442437 [TBL] [Abstract][Full Text] [Related]
8. Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration. Opoku-Nsiah KA; Gestwicki JE Transl Res; 2018 Aug; 198():48-57. PubMed ID: 30244692 [TBL] [Abstract][Full Text] [Related]
9. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Nedelsky NB; Todd PK; Taylor JP Biochim Biophys Acta; 2008 Dec; 1782(12):691-9. PubMed ID: 18930136 [TBL] [Abstract][Full Text] [Related]
10. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Lub S; Maes K; Menu E; De Bruyne E; Vanderkerken K; Van Valckenborgh E Oncotarget; 2016 Feb; 7(6):6521-37. PubMed ID: 26695547 [TBL] [Abstract][Full Text] [Related]
11. A Practical Review of Proteasome Pharmacology. Thibaudeau TA; Smith DM Pharmacol Rev; 2019 Apr; 71(2):170-197. PubMed ID: 30867233 [TBL] [Abstract][Full Text] [Related]
12. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Paul S Bioessays; 2008 Nov; 30(11-12):1172-84. PubMed ID: 18937370 [TBL] [Abstract][Full Text] [Related]
13. Deubiquitylating enzymes and drug discovery: emerging opportunities. Harrigan JA; Jacq X; Martin NM; Jackson SP Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952 [TBL] [Abstract][Full Text] [Related]
14. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Landré V; Rotblat B; Melino S; Bernassola F; Melino G Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759 [TBL] [Abstract][Full Text] [Related]
16. Ubiquitin proteasome system as a pharmacological target in neurodegeneration. Hol EM; Fischer DF; Ovaa H; Scheper W Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921 [TBL] [Abstract][Full Text] [Related]
17. Alternative UPS drug targets upstream the 26S proteasome. Hjerpe R; Rodríguez MS Int J Biochem Cell Biol; 2008; 40(6-7):1126-40. PubMed ID: 18203645 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive profiling of protein ubiquitination for drug discovery. Xu G; Jaffrey SR Curr Pharm Des; 2013; 19(18):3315-28. PubMed ID: 23151132 [TBL] [Abstract][Full Text] [Related]